This report focuses on value-based agreements (VBAs) as a mechanism to improve access to diabetes digital health technologies while aligning payment with outcomes. It explains how VBAs shift reimbursement away from volume toward demonstrated clinical and economic value, particularly in an environment of rising diabetes prevalence and costs. The report outlines performance-based and differential pricing agreements, discusses stakeholder roles, and explores benefits such as risk sharing and real-world evidence generation. Challenges include data infrastructure, outcome definition, and regulatory complexity. The report concludes that diabetes digital ecosystems are well suited for VBAs due to measurable outcomes like HbA1c and time-in-range.

Join for free to read